Related Experiment Videos
A model-based approach for assessing in vivo combination therapy interactions.
A M Lopez1, M D Pegram, D J Slamon
1Department of Biomathematics, School of Medicine, University of California, Los Angeles, CA 90095-1766, USA. alopez@maryjo.biomath.medsch.ucla.edu
Summary
This study introduces a novel model to assess combination cancer therapy schedules, considering drug order and timing. It quantitatively defines additive effects, enabling better interpretation of synergistic or antagonistic outcomes in antitumor treatments.
Area of Science:
- Pharmacology
- Mathematical Biology
- Oncology
Background:
- Evaluating combination cancer therapy efficacy is complex due to drug scheduling.
- Existing methods often lack quantitative definitions for drug effect additivity, synergism, and antagonism.
Purpose of the Study:
- To develop and illustrate a model-based approach for evaluating combination antitumor agent schedules.
- To provide a quantitative definition of additivity for drug effects, against which synergism and antagonism can be assessed.
- To compare observed and predicted tumor growth trajectories for combination therapies.
Main Methods:
- A differential equation tumor growth/drug effect model was fitted to in vivo tumor volume data from individual mice.
- Population statistics were derived from individual parameter estimates.
- Two null hypotheses (additivity or superiority of the best single agent) were used to predict combination therapy outcomes.
- Predicted tumor growth trajectories were compared with observed data.
Main Results:
- The approach allows for quantitative interpretation of drug effects in combination therapy.
- Model-based predictions were compared against observed tumor volume data for various combination schedules.
- The study illustrates the method using a dataset involving HER-2/neu-overexpressing breast cancer xenografts treated with anti-HER-2 antibody and doxorubicin.
Conclusions:
- The presented model offers a robust framework for evaluating the efficacy of combination antitumor agent schedules.
- This quantitative approach enhances the understanding of drug interactions (additive, synergistic, antagonistic) in cancer treatment.
- The methodology provides a valuable tool for optimizing combination therapy strategies in oncology.